|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Among seven common polymorphisms in the promoter region, 5'-untranslated region (UTR) and 3'UTR of the VEGF gene, genotype distribution of the C(-634)G polymorphism differed significantly (P = 0.011) between patients with (n = 150) and without (n = 118) retinopathy, and the C allele was significantly increased in patients with retinopathy compared with those without retinopathy (P = 0.0037).
|
11978667 |
2002 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Certain SNPs in intron 2 of the VEGF gene are associated with early progression of retinopathy in Japanese patients with type 1 diabetes, though their contributions were weakened by glycemic exposure.
|
19263526 |
2009 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Meta-analysis of association between the -2578C/A polymorphism of the vascular endothelial growth factor and retinopathy in type 2 diabetes in Asians and Caucasians.
|
24751925 |
2014 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Previous studies using a candidate gene approach have uncovered a number of genetic loci that may shape this risk, such as the VEGF gene for retinopathy, the ELMO1 gene for nephropathy, and the ADIPOQ gene for coronary artery disease.
|
20835900 |
2010 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We examined the possible association of the VEGF gene polymorphisms with diabetic nephropathy and retinopathy in type 2 diabetes patients.
|
17121786 |
2007 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, until now only a handful number of genetic variants were reported to be associated with either nephropathy (ACE, ELMO1, FRMD3, and AKR1B1) or retinopathy (VEGF, AKR1B1, and EPO), and only a few studies were carried out for genetic susceptibility to cardiovascular diseases (ADIPOQ, GLUL) in patients with diabetes.
|
25169573 |
2014 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis.
|
20591524 |
2010 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To determine the potential genotype differences in the vascular endothelial growth factor (VEGF) gene in diabetic patients, which might explain the difference in terms of the development of clinical vascular complications: great vessels atherosclerosis vs. retinopathy.
|
22064697 |
2012 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The VEGF -460 genotype was predictive of retinopathy, even after controlling for blood pressure, glycemic control, duration of diabetes, and obesity (P = 0.02).
|
14988276 |
2004 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The use of VEGF inhibitors for treatment of macular edema (due to radiation retinopathy) after irradiation of UM should be considered carefully, because of the possible adverse effects on residual UM cells.
|
23077404 |
2012 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Functional polymorphisms within vascular endothelial growth factor (VEGF) gene have shown association with various conditions including diabetic neuropathy and retinopathy.
|
21596454 |
2011 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The vascular endothelial growth factor (VEGF) +405 (C/G) and -460 (T/C) polymorphisms are associated with retinopathy and possibly with nephropathy, however no information is available on their relationship with peripheral neuropathy.
|
28662688 |
2017 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These data demonstrate that multiple VEGFA variants are associated with the development of severe retinopathy in type 1 diabetes.
|
17513698 |
2007 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of neovascularization in both physiological and pathological processes, e.g., developmental and reproductive angiogenesis, proliferative retinopathies, and cancers.
|
9815760 |
1997 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1α-VEGF pathway in oxygen-induced retinopathy mice.
|
29411894 |
2018 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
RNAi of VEGF and HIF-1alpha may have therapeutic potential in ischemic retinal diseases like diabetic retinopathy.
|
17869204 |
2007 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Further, SERPINA3K blocked the overexpression of proinflammatory factors, such as VEGF, TNF-alpha, and ICAM-1, in the retina of the OIR model and in cultured retinal cells exposed to hypoxia.
|
19324842 |
2009 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, we addressed the potential relationship between prominin-1 (prom1) and vascular endothelial growth factor (VEGFA) in diabetes-induced retinopathy.
|
29076766 |
2018 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Pharmacologic intervention that inhibits the signals elicited by atRA may be effective in treating VEGF-mediated retinopathies.
|
11980848 |
2002 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This study suggests that melatonin may have potential value in the prevention and treatment of various retinal diseases associated with increase of VEGF, vascular leakage and angiogenesis.
|
27409056 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis and thus contributes to many vasoproliferative retinopathies including retinopathy of prematurity.
|
25605522 |
2015 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Using RNA interference for targeted inhibition of VEGF isoforms in conjunction with IGF-I may be preferable for suppression of HREC overgrowth in vasoproliferative retinopathies such as ROP.
|
30093937 |
2018 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The newly developed anti-Tspan12 antibody has therapeutic effects in vasoproliferative retinopathy and can enhance the potency of existing anti- vascular endothelial growth factor agents.
|
28356444 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The process of retinal neovascularization in ROP and in animal models of oxygen-induced retinopathy is complex, and involves angiogenic factors, such as vascular endothelial growth factor, and basement membrane components.
|
12930159 |
2003 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
AXT107 reduced the VEGF-induced vascular leakage that underlies macular edema in ischemic retinopathies and NVAMD.
|
28100839 |
2017 |